Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses

Stabilization of the HIV-1 Envelope glycoprotein trimer (Env) in its native pre-fusion closed conformation is regarded as one of several requirements for the induction of neutralizing antibody (nAb) responses, which, in turn, will most likely be a prerequisite for the development of an efficacious p...

Full description

Bibliographic Details
Main Authors: Alexandra Hauser, George Carnell, Kathrin Held, Guidenn Sulbaran, Nadine Tischbierek, Lisa Rogers, Georgios Pollakis, Paul Tonks, Michael Hoelscher, Song Ding, Rogier W. Sanders, Christof Geldmacher, Quentin Sattentau, Winfried Weissenhorn, Jonathan L. Heeney, David Peterhoff, Ralf Wagner
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/9/7/750
Description
Summary:Stabilization of the HIV-1 Envelope glycoprotein trimer (Env) in its native pre-fusion closed conformation is regarded as one of several requirements for the induction of neutralizing antibody (nAb) responses, which, in turn, will most likely be a prerequisite for the development of an efficacious preventive vaccine. Here, we systematically analyzed how the stepwise stabilization of a clade C consensus (ConC) Env immunogen impacts biochemical and biophysical protein traits such as antigenicity, thermal stability, structural integrity, and particle size distribution. The increasing degree of conformational rigidification positively correlates with favorable protein characteristics, leading to optimized homogeneity of the protein preparations, increased thermal stability, and an overall favorable binding profile of structure-dependent broadly neutralizing antibodies (bnAbs) and non-neutralizing antibodies (non-nAbs). We confirmed that increasing the structural integrity and stability of the Env trimers positively correlates with the quality of induced antibody responses by the immunogens. These and other data contribute to the selection of ConCv5 KIKO as novel Env immunogens for use within the European Union’s H2020 Research Consortium EHVA (European HIV Alliance) for further preclinical analysis and phase 1 clinical development.
ISSN:2076-393X